Editing test page 2
Revision as of 03:50, 14 January 2018 by Warner-admin (talk | contribs) (Text replacement - "#66FF66" to "#fee0d1")
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
| Section editor | |
|---|---|
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
Note: the page has adjuvant and perioperative regimens specific to colon cancer as well as systemic regimens for the more general category of colorectal cancer. Please see the rectal cancer page for regimens specific to rectal cancer.
1 regimens on this page
1 variants on this page
|
Guidelines
ESMO
- Early Colon Cancer: ESMO Clinical Practice Guidelines PubMed
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. PubMed
- Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. PubMed
NCCN
Adjuvant therapy
Capecitabine monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Twelves et al. 2005 | Phase III | 5-FU & Leucovorin | Non-inferior DFS |
| Kerr et al. 2016 (QUASAR 2) | Phase III | Capecitabine & Bevacizumab | Seems not superior |
Chemotherapy
- Capecitabine (Xeloda) 1250 mg/m2 PO BID on days 1 to 14
21-day cycle for 8 cycles
References
- Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. link to original article contains verified protocol PubMed
- Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016 Nov;17(11):1543-1557. link to original article contains protocol PubMed